Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
US Department of Justice
Chubb
Cantor Fitzgerald
Baxter
Chinese Patent Office
AstraZeneca
Daiichi Sankyo
Boehringer Ingelheim

Generated: April 23, 2018

DrugPatentWatch Database Preview

SOMAVERT Drug Profile

« Back to Dashboard

When do Somavert patents expire, and when can generic versions of Somavert launch?

Somavert is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in SOMAVERT is pegvisomant. One supplier is listed for this compound. Additional details are available on the pegvisomant profile page.
Summary for SOMAVERT
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 15
Drug Prices:see details
DailyMed Link:SOMAVERT at DailyMed
Drug patent expirations by year for SOMAVERT

US Patents and Regulatory Information for SOMAVERT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-001 Mar 25, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-004 Jul 31, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SOMAVERT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-002 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-001 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn SOMAVERT pegvisomant INJECTABLE;SUBCUTANEOUS 021106-003 Mar 25, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
Johnson and Johnson
Fish and Richardson
UBS
US Army
McKinsey
Medtronic
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.